Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program

Mann-Wrobel, Monica C.; Bennett, Melanie E.; Weiner, Elaine; Boyer, Robert; Ball, M. Patricia

doi:10.1016/j.schres.2010.10.030

Cited by 47 publications

(44 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although imperfect, we believe that using current smoking as a surrogate for recent smoking practice is still valid, as the rate of change in smoking practice in patients with severe mental illness is low. 26 We did, however, consider it invalid to correlate current clozapine/ norclozapine values with weight changes that predated their collection; thus, we could not use clozapine/norclozapine levels to substantiate our hypothesis.…”

Section: Discussionmentioning

confidence: 88%

Predicting Weight Gain in Patients Treated With Clozapine

Lau

Muir

Assur

et al. 2016

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Predicting Weight Gain in Patients Treated With Clozapine

Lau

Muir

Assur

et al. 2016

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Given the overlap between depression symptoms and negative schizophrenia symptoms, and the fact that other smoking studies have not reported elevated depression symptoms in SS versus CS (e.g., George et al, 2002), future studies assessing mediators of smoking lapse in this population should use instruments such as the Calgary Depression Scale (Addington, Addington, & Maticka-Tyndale, 1993), which has minimal overlap with negative symptoms, and the Positive and Negative Syndrome Scale (Kay, Fiszbein, & Opler, 1987) or Scale for the Assessment of Negative Symptoms (Andreasen, 1984) that may better differentiate between the roles of depression and negative symptoms in mediating smoking behavior in SS. A third limitation is that we did not assess several factors that contribute to smoking cessation outcomes in SS, such as self-efficacy for cessation, task persistence, and other measures of executive functioning (Mann-Wrobel, Bennett, Weiner, Buchanan, & Ball, 2011;Moss et al, 2009;Steinberg et al, 2012). The relative contributions of these factors could be examined in future studies using the current model.…”

Section: Discussionmentioning

confidence: 99%

Effects of Smoking Abstinence on Cigarette Craving, Nicotine Withdrawal, and Nicotine Reinforcement in Smokers With and Without Schizophrenia

Tidey

Colby

Xavier

2013

Nicotine & Tobacco Research

View full text Add to dashboard Cite

introduction: Schizophrenia is associated with a high prevalence of cigarette smoking. The aims of this study were to compare smokers with schizophrenia (SS) and control smokers without psychiatric illness (CS) on (a) cigarette craving and nicotine withdrawal symptom severity during a 72-hr smoking abstinence period; (b) nicotine reinforcement, before and after abstinence; and (c) latency to smoking lapse following abstinence. We also explored mediators of smoking lapse in SS and CS.

show abstract

“…Most of them think that smoking helps to alleviate negative symptoms and cognitive deficits, enhances cognitive performance, and provides psychomotor stimulation [17,89]. Generally, people with schizophrenia feel less confident about being successful in quitting and have concerns about their coping ability and potential negative symptoms following quitting [90].…”

Section: Awareness and Motivation Patients With Chd Whomentioning

confidence: 99%

Smoking Cessation in Long-Term Conditions: Is There “An Opportunity in Every Difficulty”?

Siddiqi

Dogar

Siddiqi

2013

International Journal of Population Research

View full text Add to dashboard Cite

Introduction. Smoking plays a causal role in several long-term conditions and worsens their outcomes. Focusing on six such conditions, we present a narrative review of seminal studies on the prevalence and impact of continued tobacco use on these conditions; the effectiveness of cessation interventions; the extent to which patients receive these interventions, and barriers to providing and taking up these interventions. Methods. A conceptual framework was used to identify questions for a series of focused literature reviews. Findings were synthesized and the literature was examined to identify themes common across these conditions. Results. Smoking prevalence is either similar or higher in patients with established long-term conditions compared to the general population. Continued smoking accelerates disease progression, worsens outcomes, and risks poor treatment compliance or further complications. There is strong evidence for the effectiveness of cessation interventions in achieving smoking abstinence. Despite this, only a small proportion of patients receive such interventions. Important barriers to uptake include concerns about weight management and drug safety, higher nicotine dependency and codependency, comorbidity, and misperceptions about the benefits of cessation. Conclusion. The benefits of offering smoking cessation in patients with long-term conditions are far too great for it to remain of a low priority.

show abstract

Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program

Cited by 47 publications

References 46 publications

Predicting Weight Gain in Patients Treated With Clozapine

Predicting Weight Gain in Patients Treated With Clozapine

Effects of Smoking Abstinence on Cigarette Craving, Nicotine Withdrawal, and Nicotine Reinforcement in Smokers With and Without Schizophrenia

Smoking Cessation in Long-Term Conditions: Is There “An Opportunity in Every Difficulty”?

Contact Info

Product

Resources

About